BRIACELL THERAPEUTICS CORP BCTXZ
*W EXP 99/99/999 · Equity WRT · CUSIP 107930117
- SectorHealth care
- IndustryPharmaceutical Preparations
- FilingsSEC EDGAR
* Summed across managers. Shares that two managers' reports both contain – a subsidiary's holdings that its parent's report includes too, or a sub-adviser's in its client's – are counted once. Holder counts are more reliable. Implied quarter-end price ≈ $0.10.
Trends to Q2 2026
Institutional holders
Managers reporting a position, each quarter
Numbers
| Quarter | Holders |
|---|---|
| Q2 2025 | 4 |
| Q3 2025 | 3 |
| Q4 2025 | 4 |
| Q1 2026 | 4 |
| Q2 2026 | 5 |
Buyers vs sellers
Managers adding to or starting a position, vs cutting or selling out
Numbers
| Quarter | Bought or added | Cut or sold out |
|---|---|---|
| Q3 2025 | 0 | 3 |
| Q4 2025 | 0 | 2 |
| Q1 2026 | 1 | 2 |
| Q2 2026 | 3 | 4 |
Biggest buyers
| SUSQUEHANNA INTERNATIONAL GROUP, LLP | New | +114.5k |
| HRT FINANCIAL LP | New | +67.9k |
| TWO SIGMA SECURITIES, LLC | New | +15.1k |
Biggest sellers
| Empery Asset Management, LP | Sold out | -666.6k |
| HEIGHTS CAPITAL MANAGEMENT, INC | Reduced | -226.7k |
| SABBY MANAGEMENT, LLC | Reduced | -86.0k |
| UBS Group AG | Sold out | -4.7k |
Insider purchases and sales since 1 Apr 2026
Shares bought or sold by the company's own officers, directors and 10% owners, in the open market or privately, as they reported to the SEC on Form 4 (due within two business days of the trade). Grants, option exercises, shares withheld for tax and gifts aren't included.
None reported since 1 Apr 2026.
Holders, Q2 2026
| Manager | Shares | Change |
|---|---|---|
| HEIGHTS CAPITAL MANAGEMENT, INC 0.01% of their portfolio | 313.4k $31.3k | Reduced -226.7k |
| SABBY MANAGEMENT, LLC 0.10% of their portfolio | 120.8k $11.5k | Reduced -86.0k |
| SUSQUEHANNA INTERNATIONAL GROUP, LLP 0.00% of their portfolio | 114.5k $11.5k | New |
| HRT FINANCIAL LP 0.00% of their portfolio | 67.9k $6.0k | New |
| TWO SIGMA SECURITIES, LLC 0.00% of their portfolio | 15.1k $1.4k | New |